BioMarker Strategies SnapPath® System

BioMarker Strategies is a tissue-based cancer diagnostics company that is developing the SnapPath® live tumor cell testing system* to improve the treatment of cancer.

Supported with funding from the National Cancer Institute, the SnapPath® system enables the generation of PathMap® Functional Signaling Profiles which help guide targeted drug development and treatment selection, including drug combinations.

SnapPath® units are being utilized in human clinical and preclinical studies for advanced melanoma and other solid tumors.

Service Provided by Sparton:

Biomarker Strategies partnered with the Sparton design and manufacturing teams to develop a system that would standardize and automate biopsy sample preparation and live cell molecular analysis. The detailed services provided by Sparton include:

Full System Design

  • Electronics design
  • Software design
  • Mechanical engineering
  • Fluidics system design
  • Thermal management design
  • Systems engineering
  • Disposable development (partnership)
  • Prototype builds

Key Challenges:

  • Proven expertise in complex fluidics
  • Experience in interfacing the disposable with the instrumentation
  • Deep understanding of the FDA regulatory environment
  • Specific knowledge in working with in vitro diagnostics devices

End Result

The SnapPath® System has been recognized by various industry experts for its novel technology. In one report, SnapPath® is ranked as 1 of 6 promising technologies that will change cancer testing. Sparton is proud to have played a key role in the development of this emerging technology.

Awards

MDEA-2012

 

*For Research Use Only (RUO) device.  Not for use in diagnostic procedures.

← Back to all